{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:23:55Z","timestamp":1785335035725,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Oncology Center of Excellence, Food and Drug Administration","award":["U01FD005938"],"award-info":[{"award-number":["U01FD005938"]}]},{"name":"Oncology Center of Excellence, Food and Drug Administration","award":["U01FD005938"],"award-info":[{"award-number":["U01FD005938"]}]},{"name":"Oncology Center of Excellence, Food and Drug Administration","award":["U01FD005938"],"award-info":[{"award-number":["U01FD005938"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA015083"],"award-info":[{"award-number":["P30CA015083"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA108671"],"award-info":[{"award-number":["P01CA108671"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA108671"],"award-info":[{"award-number":["P01CA108671"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA108671"],"award-info":[{"award-number":["P01CA108671"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA108671"],"award-info":[{"award-number":["P01CA108671"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"DOI":"10.1186\/s12874-025-02617-y","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T10:38:14Z","timestamp":1754563094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies"],"prefix":"10.1186","volume":"25","author":[{"given":"Gita","family":"Thanarajasingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brie N.","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallorie H.","family":"Fiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina L.","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Murugappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Kluetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou C.","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"2617_CR1","unstructured":"Friends of Cancer Research. Broadening the Definition of Tolerability in Cancer Clinical Trials to Better Measure the Patient Experience. 2018. Website: https:\/\/friendsofcancerresearch.org\/wp-content\/uploads\/Comparative-Tolerability-Whitepaper_FINAL.pdf. Accessed 11 July 2025."},{"key":"2617_CR2","unstructured":"U.S Food and Drug Administration. Core Patient-Reported Outcomes in Cancer Clinical Trials. 2021. Website: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/core-patient-reported-outcomes-cancer-clinical-trials. Accessed 11 July 2025."},{"key":"2617_CR3","unstructured":"U.S. Food and Drug Administration. Submitting Patient-Reported Outcome Data in Cancer Clinical Trials. 2023. Website: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/submitting-patient-reported-outcome-data-cancer-clinical-trials. Accessed 11 July 2025."},{"key":"2617_CR4","unstructured":"U.S Food and Drug Association. 6th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop. In Proceedings of the FDA Public Workshop. U.S. Food and Drug Administration. 2021. https:\/\/www.fda.gov\/news-events\/fda-meetings-conferences-and-workshops\/fda-public-workshop-6th-annual-clinical-outcome-assessment-cancer-clinical-trials-workshop-07212021. Accessed 11 July 2025."},{"issue":"6","key":"2617_CR5","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/s2352-3026(25)00035-3","volume":"12","author":"A Major","year":"2025","unstructured":"Major A, Dueck AC, Thanarajasingam GT. Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era. Lancet Haematol. 2025;12(6):e451\u201362. https:\/\/doi.org\/10.1016\/s2352-3026(25)00035-3.","journal-title":"Lancet Haematol"},{"issue":"6","key":"2617_CR6","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1016\/s2352-3026(25)00036-5","volume":"12","author":"V Bhatnagar","year":"2025","unstructured":"Bhatnagar V, Dueck AC, Efficace F, et al. Beyond maximum grade: using patient-generated data to inform tolerability of treatments for haematological malignancies. Lancet Haematol. 2025;12(6):e463\u20139. https:\/\/doi.org\/10.1016\/s2352-3026(25)00036-5.","journal-title":"Lancet Haematol"},{"key":"2617_CR7","unstructured":"Snyder C, Brundage M, Smith KC, Bantug ET, Tolbert EE, Little E, Blackford AL, Aaronson NK, Ganz PA, Garg R, Fisch M, Hoffman V, Reeve BB, Stotsky-Himelfarb E, Stovall E, Zachary M. Testing Ways to Display Patient-Reported Outcomes Data for Patients and Clinicians. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2018. PMID: 37315167."},{"key":"2617_CR8","doi-asserted-by":"publisher","unstructured":"Brundage MD, Smith KC, Little EA, Bantug ET, Snyder CF; PRO Data Presentation Stakeholder Advisory Board. Communicating patient-reported outcome scores using graphic formats: results from a mixed-methods evaluation. Qual Life Res. 2015;24(10):2457\u201372. https:\/\/doi.org\/10.1007\/s11136-015-0974-y. Epub 2015 May 27. PMID: 26012839; PMCID: PMC4891942","DOI":"10.1007\/s11136-015-0974-y"},{"key":"2617_CR9","doi-asserted-by":"publisher","unstructured":"Snyder C, Smith K, Holzner B, Rivera YM, Bantug E, Brundage M; PRO Data Presentation Delphi Panel. Making a picture worth a thousand numbers: recommendations for graphically displaying patient-reported outcomes data. Qual Life Res. 2019;28(2):345\u2013356. https:\/\/doi.org\/10.1007\/s11136-018-2020-3. Epub 2018 Oct 10. PMID: 30306533; PMCID: PMC636386","DOI":"10.1007\/s11136-018-2020-3"},{"key":"2617_CR10","unstructured":"U.S. Food and Drug Association. (2023, March 17). Project Patient Voice. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-patient-voice"},{"issue":"6","key":"2617_CR11","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1016\/s2352-3026(25)00027-4","volume":"12","author":"GT Thanarajasingam","year":"2025","unstructured":"Thanarajasingam GT, Major A, Bhatnagar V, et al. Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series. Lancet Haematol. 2025;12(6):e403\u20136. https:\/\/doi.org\/10.1016\/s2352-3026(25)00027-4.","journal-title":"Lancet Haematol"},{"issue":"6","key":"2617_CR12","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/S2352-3026(25)00051-1","volume":"12","author":"PJ Br\u00f6ckelmann","year":"2025","unstructured":"Br\u00f6ckelmann PJ, Scheffer Cliff ER, Iacoboni G, et al. Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies. The Lancet Haematology. 2025;12(6):e470\u201381. https:\/\/doi.org\/10.1016\/S2352-3026(25)00051-1.","journal-title":"The Lancet Haematology"},{"issue":"10","key":"2617_CR13","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.1016\/S1470-2045(20)30319-3","volume":"21","author":"MH Fiero","year":"2020","unstructured":"Fiero MH, Pe M, Weinstock C, King-Kallimanis BL, Komo S, Klepin HD, Gray SW, Bottomley A, Kluetz PG, Sridhara R. Demystifying the estimand framework: a case study using patient-reported outcomes in oncology. Lancet Oncol. 2020;21(10):e488\u201394. https:\/\/doi.org\/10.1016\/S1470-2045(20)30319-3. (PMID: 33002444).","journal-title":"Lancet Oncol"},{"key":"2617_CR14","doi-asserted-by":"publisher","unstructured":"Mazza GL, Mead-Harvey C, Mascarenhas J, Yacoub A, Kosiorek HE, Hoffman R, Dueck AC, Mesa RA; Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. Lancet Haematol. 2022;9(1):e38-e48. https:\/\/doi.org\/10.1016\/S2352-3026(21)00343-4. PMID: 34971581; PMCID: PMC9098160.","DOI":"10.1016\/S2352-3026(21)00343-4"},{"key":"2617_CR15","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual (3rd Edition). Published by: European Organisation for Research and Treatment of Cancer, Brussels 2001."},{"issue":"5","key":"2617_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365. (PMID: 8433390).","journal-title":"J Natl Cancer Inst"},{"key":"2617_CR17","unstructured":"PROMIS Scoring Manuals, PROMIS Profile (Adult) Scoring Manual. Available at http:\/\/www.healthmeasures.net\/promis-scoring-manuals. Accessed 11 July 2025."},{"key":"2617_CR18","unstructured":"FACIT.org, Functional Assessment of Cancer Therapy - General Scoring Manual. Available at http:\/\/www.facit.org\/measures\/fact-g. Accessed 11 July 2025."},{"key":"2617_CR19","doi-asserted-by":"publisher","unstructured":"Coon CD, Schlichting M, Zhang X. Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13. Patient. 2022;15(6):691\u2013702. https:\/\/doi.org\/10.1007\/s40271-022-00584-w. Epub 2022 Jun 30. PMID: 35771392; PMCID: PMC9585005.","DOI":"10.1007\/s40271-022-00584-w"},{"issue":"9","key":"2617_CR20","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1093\/rheumatology\/keab014","volume":"60","author":"CO Bingham","year":"2021","unstructured":"Bingham CO, Butanis AL, Orbai AM, Jones M, Ruffing V, Lyddiatt A, Schrandt MS, Bykerk VP, Cook KF, Bartlett SJ. Patients and clinicians define symptom levels and meaningful change for PROMIS pain interference and fatigue in RA using bookmarking. Rheumatology (Oxford). 2021;60(9):4306\u201314. https:\/\/doi.org\/10.1093\/rheumatology\/keab014. (PMID:33471127;PMCID:PMC8633670).","journal-title":"Rheumatology (Oxford)"},{"key":"2617_CR21","doi-asserted-by":"publisher","unstructured":"Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey A. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 2016;17(5):663\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(16)00038-3. Epub 2016 Apr 12. PMID: 27083333; PMCID: PMC4910515.","DOI":"10.1016\/S1470-2045(16)00038-3"},{"issue":"6","key":"2617_CR22","doi-asserted-by":"publisher","first-page":"e490","DOI":"10.1016\/S2352-3026(20)30067-3","volume":"7","author":"G Thanarajasingam","year":"2020","unstructured":"Thanarajasingam G, Leonard JP, Witzig TE, Habermann TM, Blum KA, Bartlett NL, Flowers CR, Pitcher BN, Jung SH, Atherton PJ, Tan A, Novotny PJ, Dueck AC. Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematol. 2020;7(6):e490\u20137. https:\/\/doi.org\/10.1016\/S2352-3026(20)30067-3. (PMID:32470440;PMCID:PMC7457391).","journal-title":"Lancet Haematol"},{"key":"2617_CR23","doi-asserted-by":"publisher","unstructured":"Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 Nov;5(11):e563-e598. https:\/\/doi.org\/10.1016\/S2352-3026(18)30051-6. Epub 2018 Jun 18. Erratum in: Lancet Haematol. 2019;6(3):e121. PMID: 29907552; PMCID: PMC6261436.","DOI":"10.1016\/S2352-3026(18)30051-6"},{"key":"2617_CR24","doi-asserted-by":"publisher","unstructured":"Snyder C, Smith K, Holzner B, Rivera YM, Bantug E, Brundage M; PRO Data Presentation Delphi Panel. Making a picture worth a thousand numbers: recommendations for graphically displaying patient-reported outcomes data. Qual Life Res. 2019;28(2):345\u2013356. https:\/\/doi.org\/10.1007\/s11136-018-2020-3. Epub 2018 Oct 10. PMID: 30306533; PMCID: PMC6363861.","DOI":"10.1007\/s11136-018-2020-3"},{"key":"2617_CR25","unstructured":"U.S. Food and Drug Administration. FDA Public Workshop: 6th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop. 2021. Website: https:\/\/www.fda.gov\/news-events\/fda-meetings-conferences-and-workshops\/fda-public-workshop-6th-annual-clinical-outcome-assessment-cancer-clinical-trials-workshop-07212021. Accessed 11 July 2025."},{"issue":"25","key":"2617_CR26","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","volume":"379","author":"MM Gounder","year":"2018","unstructured":"Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018;379(25):2417\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1805052. (PMID:30575484;PMCID:PMC6447029).","journal-title":"N Engl J Med"},{"key":"2617_CR27","doi-asserted-by":"publisher","unstructured":"Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials. 2021;18(1):104\u2013114. https:\/\/doi.org\/10.1177\/1740774520975120. Epub 2020 Dec 1. PMID: 33258687; PMCID: PMC7878323.","DOI":"10.1177\/1740774520975120"},{"key":"2617_CR28","unstructured":"Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints. Website: https:\/\/www.sisaqol-imi.org\/"},{"key":"2617_CR29","unstructured":"McWhite C, Wilke C (2024). _colorblindr: Simulate colorblindness in R figures_. R package version 0.1.0, URL https:\/\/github.com\/clauswilke\/colorblindr."}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02617-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-025-02617-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02617-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T10:38:17Z","timestamp":1754563097000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-025-02617-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2617"],"URL":"https:\/\/doi.org\/10.1186\/s12874-025-02617-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4888383\/v1","asserted-by":"object"}]},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All trials were approved by institutional review boards or ethics committees at each site and written informed consent was obtained from all participants prior to enrollment. This study adhered to the ethical standards of the Declaration of Helsinki. The Mayo Clinic IRB deemed secondary analysis of clinical trial data and anonymous Zoom polling of stakeholder preferences as exempt (IRB# 22\u2013010586).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}